Comparative Effectiveness and Safety of Upadacitinib vs Risankizumab for Ulcerative Colitis.

The treatment landscape of moderate-to-severe ulcerative colitis (UC) has diversified with the incorporation of Janus kinase inhibitors (JAKis) and interleukin (IL) antagonists. Upadacitinib, a selective JAK-1 inhibitor, and risankizumab, an inhibitor of the p19 subunit of IL-23, have demonstrated efficacy for UC in randomized trials.1,2 However, head-to-head comparisons of these therapies are needed to guide treatment positioning. We therefore compared the effectiveness and safety of upadacitinib and risankizumab in a real-world UC cohort.